US Edition…And Then the Medicine for a Rare Childhood Disease Suddenly Became 400 Times More Expensive
Researchers at Erasmus MC discovered that a group of children with a fatal condition benefit from an old drug that costs next to nothing. A Swedish pharmaceutical company obtained the monopoly and is now marketing the drug for an exorbitant amount.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Researchers at Erasmus MC discovered that a group of children with a fatal condition benefit from an old drug that costs next to nothing. A Swedish pharmaceutical company obtained the monopoly and is now marketing the drug for an exorbitant amount.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
